0 Replies
Phase 1 Clinical Trial of Anticancer Drug MRX34 Underway
AUSTIN, TX (May 13, 2013)– Mirna Therapeutics, Inc., a biotechnology company pioneering microRNA (miRNA) replacement therapies for cancer,
announced today that it has initiated a Phase 1 clinical study of MRX34, the first miRNA to advance into a human clinical trial... Contine Reading & Discuss→
0 Replies
- Nominated RG-101 in HCV as First microRNA Candidate for Clinical Development-
- Maintained Strong Financial Position with Over $90 million in Cash-
LA JOLLA, Calif., May 14, 2013 /PRNewswire/ – Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today provided... Contine Reading & Discuss→
0 Replies
Call for papers for an open special issue on small/microRNAs:
Small RNAs: Revolutionizing the Genomics Landscape
The editors invite researchers to contribute original research articles as well as review articles focused on the use, development, or the application of genomics tools for investigating the role of small RNAs at the... Contine Reading & Discuss→
0 Replies
NEW YORK, April 8, 2013 /PRNewswire/ – Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostics for use in personalized medicine, today announced that the company is presenting a late-breaking abstract at the AACR Annual Meeting 2013, in Washington D.C. The abstract is titled “Exosome profiling of mRNAs and miRNAs in... Contine Reading & Discuss→
0 Replies
Research Published in the New England Journal of Medicine Demonstrates Marked and Long-Lasting Antiviral Activity Against HCV for Santaris Pharma A/S’ Miravirsen, the First MicroRNA-Targeted Drug to Enter Clinical Trials
HOERSHOLM, Denmark and SAN DIEGO, March 27, 2013 /PRNewswire/ — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the... Contine Reading & Discuss→
0 Replies
Dr. Lucrecia Alvarez is currently editing one of the Springer Book Series on Methods in Molecular Biology entitled “Structural and Functional RNA Mapping” and is looking for contributions:
“All I am asking the authors to do is to present their routinely laboratory protocols in a define format and, therefore, there... Contine Reading & Discuss→
0 Replies
Award Strengthens Growing Portfolio of microRNAs in Viral Infection
PHILADELPHIA and REHOVOT, Israel, March 18, 2013 /PRNewswire/ – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces receipt of a Notice of Allowance from the U.S. Patent Office related to U.S. Patent Application No. 12/517,760... Contine Reading & Discuss→
0 Replies
miRagen Therapeutics, Inc. Exclusively Licenses Intellectual Property from the University of Glasgow for microRNA-145
IP generated as a result of collaboration between researchers from miRagen, the University of Glasgow and the University of Cambridge
BOULDER, Colo., Mar 05, 2013 (BUSINESS WIRE) — –Preliminary results in pre-clinical models show significant promise... Contine Reading & Discuss→
0 Replies
Researchers at the University of Texas Southwestern Medical Center and Baylor Institute for Immunology Research have identified a novel expression signature in patients with DiGeorge Syndrome. DiGeorge Syndrome occurs because of a chromosomal deletion in 22q11.2, resulting in the hemizygous deletion of > 60 genes and 4 microRNAs. Peripheral blood... Contine Reading & Discuss→
